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Abstract
Polyomavirus type BK was first recognized in 1971 from the urine of a renal transplant recipient
with unilateral ureteral stenosis. BK virus-related nephropathy was rarely reported before 1995.
However, this virus has recently been reported as a cause of interstitial nephritis up to 5% of renal
transplant recipients. Persistent polyomavirus replication in renal allograft recipients was identified
as an important cause of progressive graft dysfunction and graft loss, especially among those
treated with strong immunosuppressive regimens. We report on a case of type BK virus nephropathy
in our centre. The definitive diagnosis is based on renal biopsy findings. The presence of abundant
decoy cells in urine is a valuable adjuvant diagnostic parameter. The detection of BK virus DNA in
the plasma by polymerase-chain-reaction assay is a promising screening tool. Cautious use of
immunosuppressive therapy to balance the risk between graft rejection and viral replication is the
mainstay treatment at present for BK virus nephropathy in renal transplant recipients. Future
development of antiviral therapy and improvement in diagnostic tools are needed.
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O R I G I N A L
A R T I C L E
INTRODUCTION
Polyomavirus type BK was found in 1971 and was named
after a renal allograft recipient named B.K. who
developed ureteric stenosis five months after renal
transplantation (1). It became prevalent in transplant
recipients only in recent years since the introduction of
more potent immunosuppressants such as tacrolimus and
mycophenolate mofetil. We encountered a typical case
and would like to share our experience below.
CASE REPORT
A 36-year-old man with previous good health was
found to have chronic renal failure in March 1998.
Ultrasonogram of kidney showed diffuse parenchymal
disease. Renal biopsy showed immunoglobulin A
nephropathy with crescentic glomerulonephritis and 50%
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suppressants. Mycophenolate mofetil was taken off and
tacrolimus was converted back to cyclosporin A.
Creatinine upon discharge was stabilized at around 260
to 280 µmol/L.
His disease course was monitored with urine examination
for decoy cells, which was persistently positive despite
the reduction of immunosuppressants. The creatinine
further deteriorated from 347 to 462 µmol/L in January
2002. Cyclosporin level was on the high side and the
dose was reduced. Ultrasonogram of graft kidney was
unremarkable. A third graft biopsy was done on
December 27, 2001 and it showed marked decrease of
polyoma virus. Interstitial inflammation was compatible
with type IB acute graft rejection. There was marked
tubular injury with acute tubular necrosis, probably
sclerosed glomeruli. He failed to respond to a course of
pulse methylprednisolone followed by oral steroid. His
disease course was complicated by pulmonary
tuberculosis and he received a 1-year course of anti-
tuberculous treatment. He was put on peritoneal dialysis
for the end-stage renal disease in December 1998. He
also developed hypertension and was put on metoprolol
and amlodipine since 1999. The dialysis course was
uneventful.
He had a cadaveric renal transplant on October 12, 2000.
Transient elevation of alanine aminotransferase over 400
U/L was noted post-operatively and gradually came down
to 131 U/L. No specific cause was found. Hepatitis B
surface antigen, anti-hepatitis C virus antibody and
cytomegalovirus (CMV) pp65 antigen were all negative.
He had good diuresis postoperatively and creatinine upon
discharge was 125 µmol/L. The immunosuppressive
therapy included cyclosporin A 150 mgom and 125 mg
pm, mycophenolate mofetil 500 mg twice a day and
prednisolone 20 mg daily. The creatinine on follow-up
was around 130-150 µmol/L. Cyclosporin level was
within therapeutic range. Septrin 480 mg twice a day
was given initially for Pneumocystic carinii prophylaxis
(PCP) and was stopped later because of liver impairment.
Alanine aminotransferase was persistently around 100
U/L.
The patient was well until March 2001 when the
creatinine progressively rose from 150 to 180 µmol/L
and then up to 200 µmol/L. There was no history of taking
herbs or over-the-counter medications. Blood pressure
and hydration status were normal. Urine output was
around 2 to 3 L per day. Physical examination did not
reveal fever or graft tenderness. Urine microscopy and
culture was unremarkable. Cyclosporin level was 154
µg/L, which was within the therapeutic range. Doppler
ultrasonogram of graft kidney was normal. Renal biopsy
showed acute rejection, grade IB (Banff criteria) with
small amount mesangial deposits. He was treated with
pulse methylprednisolone 500 mg daily for three doses
followed by prednisolone 30 mg daily. Cyclosporin A
was converted to tacrolimus 7 mg twice a day.
Mycophenolate mofetil was kept at 500 mg twice a day.
The creatinine level was stabilized at around 160 to 180
µmol/L. Urine output remained good.
However, his renal function deteriorated again in
November 2001, with creatinine rising up to 280 µmol/
L. Second graft renal biopsy was performed on
November 5, 2001 and it showed abundant polyoma virus
infection (Figs. 1 and 2). No graft rejection was noted.
The urine exam also showed abundant decoy cells (Fig.
3). He was managed with reduction of immuno-
Figure 1. Renal medullary tissue showing tubular epithelial cells
with nuclear enlargement, basophilic intranuclear inclusion
(Hematoxylin and eosin, 200x).
Figure 2. Renal biopsy showing tubular necrosis and typical viral
intranuclear inclusions (Hematoxylin and eosin, 400x)
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was asymptomatic and serum creatinine showed
progressive improvement. The latest creatinine was
around 320 µmol/L (Fig. 4). Cyclosporin trough level
was less than 25 µg/L. The current immunosuppressive
regime was cyclosporin A 50 mg morning and 25 mg
evening and prednisolone 10 mg daily.
DISCUSSION
Polyomavirus type BK is a non-enveloped, circular,
double-stranded DNA virus. The seroprevalence in adults
is 60% to 80% worldwide. The primary infection
commonly occurs in childhood by the oral or respiratory
route and usually passes without any symptom. After
the primary infection, the polyomavirus remains latent
in the urogenital tract. Asymptomatic reactivation can
occur spontaneously in immunocompetent persons but
are more frequent in those with diminished cellular
immunity such as renal allograft recipients. Overt clinical
disease from polyomavirus infection is rare and is related
to the degree of compromised immunity. In the review
by Nickeleit et al (2), they found that in four studies
involving more than 600 renal allograft recipients,
reactivation of BK virus was associated only
inconsistently with ureteral stenosis or varying degree
of graft dysfunction.
The infection is often difficult to treat and leads to graft
failure in as many as 40% of the affected patients (3).
The patient usually presents between 2 and 60 (median,
9) months after transplantation and has high serum
creatinine concentration that mimics either acute tubular
necrosis or rejection. BK virus associated interstitial
secondary to polyoma virus infection. He was treated
with three doses of methylprednisolone 500 mg daily
followed by prednisolone 10 mg daily. Mycophenolate
mofetil 250 mg twice a day was resumed in view of
rejection. Creatinine level remained static at around 440
µmol/L and showed gradual improvement to around 300
µmol/L on follow-up.
Creatinine level was static at around 300 µmol/L for one
month and it rose again up to 420 µmol/L in late January
2002. Alanine aminotransferase increased from normal
to 120 U/L. The fourth and latest graft biopsy was taken
on February 1, 2002, which showed type IA to IB acute
rejection, features similar to the previous biopsy finding.
Polyoma virus could still be seen. Mycophenolate mofetil
was withheld. Alanine aminotransferase spontaneously
came down to 40 to 60 U/L. Cytomegalovirus pp65 was
negative. Creatinine improved to 360 µmol/L upon
discharge.
The patient was admitted again in March 2002 because
of low-grade fever. Sepsis work-up was unremarkable.
Chest x-ray showed suspicious miliary shadows. Work-
up for pulmonary tuberculosis including broncho-
alveolar lavage for acid-fast-bacilli smear was negative.
Bronchoscopy did not show endobronchial lesion. He
was empirically treated with a course of antibiotics with
fever coming down. However, cytology from broncho-
alveolar lavage later showed PCP and yeast like
organism. He was treated as PCP infection with Septrin
three tablets thrice a day, which was reduced to two
tablets thrice a day later because of worsening of renal
function. Creatinine upon discharge was around 500
µmol/L. He was followed-up at our transplant clinic. He
Figure 3. Urine cytology shows polyoma virus infected cells (ie,
decoy cell) from patient's urine. The homogenous "ground glass"
intranuclear inclusion bodies are well demonstrated (Papanicolaou
stain, 400x)
Figure 4. Summarized serial change of serum creatinine level with
temporal  relat ionship with var ious events.  RT = renal
transplantation; MP = methylprednisolone; FK 506 = tacrolimus;
CsA = cyclosporin; MMF = mycophenolate mofetil; RB = renal
biopsy; AR = acute rejection; PCP = pneumocystic carinii
pneumonia
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nephritis has not yet been described in other allograft
recipients and is rare in patients with other types of
immunodeficiency. This may suggest that the allergenic
immune environment within the renal allograft might be
conducive to local reactivation of the virus. (4)
The BK virus is an important cause of progressive graft
dysfunction and graft loss among those treated with
immunosuppressive regimens that includes tacrolimus
or mycophenolate mofetil. It has been reported that
transplant recipients with diabetes, and BK virus/JC virus
seropositive donors are at particular risk of disease. Binet
et al (5) found that all their patients with polyomavirus
graft disease received heavy immunosuppressive therapy,
especially tacrolimus. Binet suggested that taciolimus
with a combination of risk factors played a key role in
promoting manifest viral disease. The risk factors could
be a high dose of tacrolimus in association with repeated
rejection episodes leading to tubular cell injury and
subsequent differentiation have been shown to promote
viral replication. The profound graft dysfunction was
likely due to the severe tubular necrosis, which is not
seen in rejection and drug toxicity. Since polyomavirus
was never cleared from the graft, frank tubular cell
necrosis and denudation of the basal membrane persisted.
The same mechanism can be applied to our case. The
patient initially had graft rejection. Large dose steroid
and taciolimus was added. However the intensified
immunosuppressant activated the polyoma virus which
further damaged the kidney, resulting in a vicious cycle.
The key to establishing the diagnosis is the recognition
of BK virus inclusions in the renal tubular cells and
glomerular epithelial cells in allograft-biopsy specimens.
Cells infected with the virus cause interstitial
inflammatory cell infiltrate and focal inflammation of
the tubules that may mimic acute rejection. From the
study of Ahuja et al (6), more abundant B cells (CD20)
and fewer cytotoxic T cells in allograft seems to be
characteristic of polyomavirus infection when compared
with patients with acute rejection. Diagnosis with
immunostaining for T and B cells and cytotoxic T cells
can be used as a guide to differentiate polyomavirus
infection from acute rejection. The identification of
v i r a l l y  i n f e c t e d  c e l l s  r e l i e s  h e a v i l y  o n
immunohistochemical analysis or in-situ hybridization.
(7) Electronic microscopic examination of negatively
stained urine specimens provides an additional valuable
diagnostic tool for the detection of polyomavirus
infection. The technique is rapid, noninvasive, and
relatively inexpensive.
Allograft tissue biopsy is the gold standard for the
definitive diagnosis of BK virus nephropathy. However
its invasive nature is inappropriate for screening or
monitoring. Culture of virus from body fluids or tissue
is time-consuming and is not available in most
laboratories. Renal allograft dysfunction does not
develop in most patients with raised serum BK virus
antibody concentration. The detection of "decoy cells"
(virally-infected transitional cells, identified by their
typical ground glass intranuclear inclusions on cellular
smears stained by the Papanicolaou method) in urine also
does not predict the clinical disease, since it is associated
with BK virus nephropathy in about 28% of cases. The
viral load is not directly assessed by the amount of decoy
cells in the urine. However, the presence of a critical
number of decoy cells represents a practical way to
evaluate the cytopathic effects of viral reactivation.
Nickeleit et al (2) report the detection of BK virus DNA
in the plasma by polymerase chain reaction (PCR) assay
of nine patients with biopsy-proven BK virus
nephropathy. The result showed that the test had 100%
sensitivity and a specificity of 88% for detecting BK virus
nephropathy. This finding offers a potential method for
screening and following patients infected with this virus.
Based on the present evidence, we believe that screening
with urine decoy cells followed by graft renal biopsy
can diagnose most  BK nephropathy in renal
transplantation recipients. With the development of
plasma PCR for BK polyomavirus, the invasive renal
biopsy may not be necessary in some of the patients.
Large studies are needed to verify the reliability of the
diagnosis of BK nephropathy based on plasma PCR.
There is no established therapeutic guideline for
polyomavirus infection in the renal transplant recipients.
There is no proof of the efficacy of glucocorticoid and
human immunoglobulins. At present, no effective
antiviral therapy is available. Retinoic acid, 5-bomo-2-
deoxyuridine, cidofovir and gyrase inhibitor have
antiviral activity in vitro but have not been studied
clinically in a systematic fashion (4). Other associated
conditions, such as ureteral stenosis, bacterial urinary
tract infections, and cytomegalovirus disease, should be
identified and treated (8). Reduction of immuno-
suppressive drugs decreases the viral load but increases
the risk of rejection. Treatment should include judicious
lowering of the dose of immunosuppressive agent, and
the patient should be monitored closely for the onset of
rejection. One previous publication reported a beneficial
effect of tacrolimus discontinuation and switching over
to Cyclosporin (9). However the virus never cleared from
the graft and renal function deteriorated continuously.
Unfortunately, most patients with interstitial nephritis
due to BK virus slip into disheartening cycle, alternating
between viral interstitial nephritis and rejection
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precipitated by virus-induced immune activation and
lowered dose of immunosuppressive drugs.
Polyomavirus (type BK) is an important emerging
complication after renal transplantation and is associated
with an ominous prognosis. BK virus nephropathy might
be promoted by recurrent rejection episodes with tubular
injury and high dose taciolimus rescue therapy. The
definitive diagnosis is based on renal biopsy findings.
The presence of abundant decoy cells in the urine of renal
transplant recipients is a strong indication for further
work-up in high-risk cases. Emerging use of plasma DNA
PCR assay has played a role in diagnosis. Currently there
is no effective antiviral drug to cure the infection. Viral
replication seems to be reduced by easing up on
immunosuppressive therapy and this improves the graft
dysfunction. At present cautious use of immuno-
suppressive therapy to balance the risk between graft
rejection and viral replication is the mainstay of treatment
of BK virus nephropathy in renal transplant recipients.
Future development of anti-viral therapy and
improvement in diagnostic tools are needed.
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